Fujian Ke Rui Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise jointly invested by Fujian Institute of Microbiology of the State Administration of Medicine and American businessmen. Fujian Ke Rui Pharmaceutical Co., Ltd. relies on the high-tech achievements and technical force of the Institute to research, develop and produce new microbial drugs, integrating scientific research, production and trade. 200 1 was awarded "High-tech Enterprise" by Fujian Science and Technology Department. Professor Cheng, Chairman of the Board, is an expert in microbiology and biotechnology and a doctoral supervisor. He studied at the Italian University of Padua, the University of Vinola and the Massachusetts Institute of Technology, and is now the editorial board of the International Journal of Antibiotics and the China Journal of Antibiotics. Ke Rui Company produces and deals in immunomodulators, raw materials for new antibiotics, medicines, traditional Chinese medicines and biochemical reagents. Cyclosporine A, the main immunosuppressant, was certified by the US Food and Drug Administration (FDA) on 1997 and sold to domestic and foreign markets. The company's raw materials (cyclosporine) and oral liquid obtained the GMP certificate of People's Republic of China (PRC) in June 65438+1October 65438+July 2002. Cyclosporine oral liquid-Cespine has been widely used to treat organ transplant rejection and autoimmune diseases, with good curative effect, and its price is far lower than that of similar products in China, which is very popular among clinicians and patients. In addition to the research and production of cyclosporine series products, the company is working hard to develop a new and efficient immunosuppressant-rapamycin, which is ten times stronger than cyclosporine and four times stronger than FK506, so as to provide new medical varieties and meet clinical needs. Fujian Institute of Microbiology is a professional scientific research institution supporting the research and development of new microbial drugs by the State Administration of Medicine. It is the first in China to successfully develop antibiotics produced by micromonospora-gentamicin and sisomicin, new immunosuppressants produced by fungi-cyclosporine, immune enhancers produced by Nocardia -Cebijia and Streptomyces? -lactamase inhibitor-clavulanic acid and other microbial drugs, and formed the research characteristics of finding new drugs from micromonospora, which has considerable influence at home and abroad. Ke Rui Company sincerely cooperates with its domestic and foreign counterparts and makes unremitting efforts to develop the pharmaceutical industry closely related to human survival and revitalize China.
Legal Representative: Ding Zongting
Establishment time: 1999-09-07
Registered capital: 25 million RMB.
Industrial and commercial registration number: 3500004000 10 19.
Type of enterprise: other limited liability companies
Company Address: Zai Yuan Industrial Village, Haikou, Fuqing City